/NPTX

NPTX Stock - Neuropathix, Inc.

Q: What is the analyst price target for NPTX?

Analyst price target information is not currently available for NPTX.

Q: What is NPTX's market cap?

Market capitalization information is not currently available for NPTX.

Healthcare|Biotechnology|OTC

$0.00+0.00%

+$0.00 (+0.00%) • Jun 13

GoAI Score

Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.

HOLD

Medium Confidence

Momentum

Momentum Score

Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.

Sentiment

Sentiment Score

Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).

Risk Score

Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.

Price Target

Average analyst price target from the last quarter. Shows expected upside/downside from current price.

+10.0%upside

Target: $0.00

AI Analysis PreviewPremium

Real-time AI-powered market analysis

Precise entry/exit price targets

Risk assessment & position sizing

Unlock GoAI Insights for NPTX

Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.

Buy/Sell Signals

94% win rate on Alpha signals

Deep Analysis

Institutional-grade thesis

Real-Time Alerts

SMS & push notifications

Risk Scoring

Multi-factor analysis

Free 14-day trial • No credit card required

Financial Statements

Revenue & Profitability Trend

FY2017

FY2018

FY2019

FY2020

FY2021

← Swipe to see more →

Revenue

Net Income (Profit)

Net Loss

Key Metrics

Market CapN/A

P/E RatioN/A

Beta1.65

52W High$0.04

52W Low$0.00

Avg VolumeN/A

Income Statement (Fiscal Year)

Metric	FY2021	FY2020	FY2019	FY2018	FY2017
Revenue	$183.48B	N/A	$126,027	$173,889	$1,154
Gross Profit	$183.48B	N/A	$126,027	$173,889	$1,154
Gross Margin	100.0%	N/A	100.0%	100.0%	100.0%
Operating Income	$-2,940,636	$-4,473,728	$-2,329,117	$-1,061,808	$-22,443
Net Income	$-3,992,375	$-5,569,687	$-4,565,785	$936,815	$-22,443
Net Margin	-0.0%	N/A	-3622.9%	538.7%	-1944.8%
EPS	$-0.05	$-0.07	$-0.06	$0.01	$-0.00

Company Overview

Neuropathix, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutics from its proprietary synthetic cannabinoid derivatives platform. It engages in the research and development of chemical entities, such as KLS-13019, KLS-13023, and KLS-13022, as well as its related molecules; and synthetic cannabidiol therapeutics through pre-clinical drug discovery and development processes for use in the disease indications of chemotherapy induced peripheral neuropathy, overt hepatic encephalopathy, mild traumatic brain injury, and chronic traumatic encephalopathy. The company was formerly known as Kannalife, Inc. and changed its name to Neuropathix, Inc. in November 2020. Neuropathix, Inc. was founded in 2010 and is based in Doylestown, Pennsylvania.

Visit Website